Sienna Biopharmaceuticals, Inc.
SNNA
SNNA was delisted on the 16th of December, 2019.
34 hedge funds and large institutions have $178M invested in Sienna Biopharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 34 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$67.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$34.7M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$16.7M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$16.5M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$10.1M |
Top Sellers
SNNA Hedge Fund Activity: Q3 2017 in Review
34 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q3 2017, worth a combined $178M.
Buyers outnumbered sellers: 34 funds opened new SNNA positions and 0 closed out — a net gain of 34 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $67.6M.
- 34 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $178M of Sienna Biopharmaceuticals, Inc. stock for Q3 2017.
- 34 funds opened new Sienna Biopharmaceuticals, Inc. positions in Q3 2017 and 0 closed out, a net change of +34 holders.
- The largest Sienna Biopharmaceuticals, Inc. buyer in Q3 2017 was Fidelity Investments, an estimated $67.6M added.
Based on aggregated 13F filings for Q3 2017.